Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
Longeveron, a clinical stage biotechnology company (NASDAQ: LGVN), announced its participation in the Emerging Growth Virtual Conference on June 12-13, 2024. The company will present on June 12 at 1:45 p.m. ET. The presentation will be webcast and accessible via the 'Events and Presentations' section of Longeveron's website. A replay will be available for 180 days post-conference. Questions can be submitted in advance or during the event.
- Longeveron's participation in the Emerging Growth Virtual Conference increases its visibility among investors.
- The webcast and replay availability for 180 days provide extended access to the presentation, potentially attracting more investors.
- No new clinical or financial data was provided in the announcement, offering information for investors to act upon.
- The press release lacks specific details on business progress or development milestones, which could leave investors wanting more substantial updates.
MIAMI, June 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.
Details for the Company’s presentation:
| Date: | Wednesday, June 12, 2024 | |
| Time: | 1:45 p.m. ET |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron presenting at the Emerging Growth Virtual Conference?
How can I access the Longeveron presentation at the Emerging Growth Virtual Conference?
How long will the replay of Longeveron's presentation be available?
What is Longeveron's stock symbol?
